Commercial

Services that require precertification for AmeriHealth Pennsylvania Members (Effective 07/01/2021)


Services that require precertification 


As of July 1, 2021, this list applies to all AmeriHealth Pennsylvania HMO and POS products, including Flex products

This applies to services performed on an elective, nonemergency basis 

Because a service or item is subject to precertification, it does not guarantee coverage. The terms and conditions of your benefit plan must be reviewed to determine if any of these services or items are excluded. 

You can find additional information regarding preapproval/precertification, member cost-sharing and prescription drug coverage on the AmeriHealth Preapproval/Precertification Requirements and Member Cost-Sharing page. 

All home-care services (including infusion therapy in the home) 


Inpatient services 


  • Acute rehabilitation admissions 
  • Elective surgical and nonsurgical inpatient admissions 
  • Inpatient hospice admissions 
  • Long term acute care (LTAC) facility admissions
  • Skilled nursing facility admissions

Cardiology procedure​​​s


Precertification is performed by AIM Specialty Health®. To access the complete list of AIM Clinical Appropriateness Guidelines for Cardiology and Arterial Ultrasound, click here.  

  • Arterial ultrasound 
  • Diagnostic coronary angiography 
  • Percutaneous coronary intervention 


Any procedure, device, or service that may potentially be considered experimental or in​​vestigational including: 


  • New emerging technology/procedures, as well as existing technology and procedures applied for new uses and treatments

P
roce​​​dures
  • Bronchial thermoplasty

    31660, 31661 
  • Cochlear implant surgery and associated supplies/bone-anchored (osseointegrated) hearing aids, implantable bone conduction hearing aids

    69714, 69715, 69717, 69718, 69930, L8619, L8627, L8628, L8629, L8690, L8691, L8692, L8693  
  • Obesity surgery

    43644, 43645, 43659, 43770, 43771, 43772, 43773, 43774, 43775, 43842, 43843, 43845, 43846, 43847, 43848, 43886, 43887, 43888, 43999  
  • Uvulopalatopharyngoplasty (UPPP)
​421​​​45 


Musculoskeletal ​​Procedures


Precertification is performed by AIM Specialty Health®. For additional information, refer to the current version of Medical Policy #00.01.66: Musculoskeletal Services.  

  • Bone graft substitutes and bone morphogenetic proteins for spine surgery 
  • Cervical decompression with or without fusion cervical disc arthroplasty 
  • Hip arthroplasty 
  • Hip arthroscopy and open procedures 
  • Knee arthroplasty
  • Knee arthroscopy and open procedures 
  • Lumbar disc arthroplasty 
  • Lumbar discectomy, foraminotomy, and laminotomy 
  • Lumbar fusion and treatment of spinal deformity (including scoliosis and kyphosis) 
  • Lumbar laminectomy 
  • Meniscal allograft transplantation of the knee 
  • Shoulder arthroplasty 
  • Shoulder arthroscopy and open procedures 
  • Treatment of osteochondral defects 
  • ​Vertebroplasty/Kyphoplasty 


Interventional pain manageme​​nt services


Precertification is performed by AIM Specialty Health®. For additional information, refer to the current version of Medical Policy #00.01.66: Musculoskeletal Services.  

  • Epidural Injection Procedures and Diagnostic Selective Nerve Root Blocks
  • Paravertebral Facet Injection/Nerve Block/Neurolysis 
  • Regional Sympathetic Nerve Block 
  • Sacroiliac joint injections 
  • ​Implanted spinal cord stimulators 


Reconstructive procedures and poten​​tially cosmetic procedures 


  • Blepharoplasty/ptosis repair

    15820, 15821, 15822, 15823, 67900, 67901, 67902, 67903, 67904, 67906, 67908, 67909​ 

  • ​Bone graft, genioplasty and mentoplasty

    21120, 21121, 21122, 21123
     
  • Breast Reconstruction

    11920, 11921, 11922, 11970, 11971, 15271, 15272, 15769, 15771, 15772, 15773, 15774, 15777, 19350, 19355, 19357, 19361, 19364, 19367, 19368, 19369, 19380, Q4100, Q4107, Q4130, S2066, S2067, S2068
     
  • Breast Reduction

    15877, 19318
     
  • Breast Augmentation/Mammoplasty

    19325​
     
  • Breast Mastopexy

    19316
     
  • Insertion of Breast Implants

    19340, 19342, 19396
     
  • Removal of Breast Implants

    19328, 19330, 19370, 19371
     
  • Canthopexy/Canthoplasty

    21280, 21282, 67950
     
  • Cervicoplasty

    15819
     
  • Chemical peels

    15788, 15789, 15792, 15793​
     
  • Dermabrasion

    15780, 15781, 15782, 15783
     
  • Excision of excessive skin and/or subcutaneous tissue

    15830, 15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839
     
  • Gender reassignment surgery

    11960, 19303, 53430, 54125, 54400, 54401, 54405, 54520, 54660, 54690, 55175, 55180, 57106, 57110, 58150, 58180, 58260, 58262, 58275, 58290, 58291, 58541, 58542, 58543, 58544, 58550, 58552, 58553, 58554, 58570, 58571, 58572, 58573, 58720
     
  • Genetically and bio-engineered skin substitutes for wound care

    C1849, Q4100, Q4101, Q4102, Q4103, Q4104, Q4105, Q4106, Q4107, Q4108, Q4110, Q4111, Q4113, Q4114, Q4115, Q4117, Q4118, Q4121, Q4122, Q4123, Q4124, Q4126, Q4127, Q4132, Q4133, Q4134, Q4135, Q4136, Q4137, Q4139, Q4140, Q4141, Q4145, Q4146, Q4147, Q4148, Q4149, Q4151, Q4152, Q4153, Q4154, Q4155, Q4156, Q4157, Q4158, Q4159, Q4160, Q4161, Q4162, Q4163, Q4164, Q4165, Q4166, Q4167, Q4168, Q4169, Q4170, Q4171, Q4173, Q4174, Q4175, Q4176, Q4177, Q4178, Q4179, Q4180, Q4181, Q4182, Q4205, Q4206, Q4208, Q4209, Q4210, Q4211, Q4214, Q4215, Q4216, Q4217, Q4218, Q4219, Q4220, Q4221, Q4222, Q4227, Q4228, Q4229, Q4230, Q4231, Q4232, Q4233, Q4234, Q4235, Q4236, Q4237, Q4238, Q4239, Q4244, Q4245, Q4246, Q4247, Q4248, Q4249, Q4250, Q4254, Q4255
     
  • Hair transplant

    15775, 15776
     
  • Injectable dermal fillers

    11950, 11951, 11952, 11954, Q2026, Q2028
     
  • Keloid removal

    13100, 13101, 13102, 13120, 13121, 13122, 13131, 13132, 13133, 13151, 13152, 13153, 14000, 14001, 14020, 14021, 14040, 14041, 14060, 14061, 14301, 14302, 15002, 15003, 15004, 15005, 15040, 15050, 15100, 15101, 15110, 15111, 15115, 15116, 15120, 15121, 15130, 15131, 15135, 15136, 15150, 15151, 15152, 15155, 15156, 15157, 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15570, 15572, 15574, 15576, 15600, 15610, 15620, 15630, 15650, 15731, 15733, 15734, 15736, 15738, 15740, 15750, 15756, 15757, 15758, 15760, 15770, 15780, 15781, 15782, 15783, 15786, 15787, 31830
     
  • Lipectomy, liposuction, or any other excess fat-removal procedure

    15832, 15833, 15834, 15835, 15836, 15837, 15838, 15839, 15876, 15877, 15878, 15879
     
  • Otoplasty

    13151, 13152, 13153, 14060, 14061, 15260, 15261, 21235, 69300, 69399
     
  • Rhinoplasty

    30400, 30410, 30420, 30430, 30435, 30450
     
  • Rhytidectomy

    15824, 15825, 15826, 15828, 15829, 15838, 15839, 15876
     
  • Scar revision

    13100, 13101, 13102, 13120, 13121, 13122, 13131, 13132, 13133, 13151, 13152, 13153, 14000, 14001, 14020, 14021, 14040, 14041, 14060, 14061, 14301, 14302, 15002, 15003, 15004, 15005, 15040, 15050, 15100, 15101, 15110, 15111, 15115, 15116, 15120, 15121, 15130, 15131, 15135, 15136, 15150, 15151, 15152, 15155, 15156, 15157, 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15570, 15572, 15574, 15576, 15600, 15610, 15620, 15630, 15650, 15731, 15733, 15734, 15736, 15738, 15740, 15750, 15756, 15757, 15758, 15760, 15770, 15780, 15781, 15782, 15783, 15786, 15787, 31830
     
  • Skin closures

    13100, 13101, 13102, 13120, 13121, 13122, 13131, 13132, 13133, 13151, 13152, 13153, 14000, 14001, 14020, 14021, 14040, 14041, 14060, 14061, 14301, 14302, 15002, 15003, 15004, 15005, 15040, 15050, 15100, 15101, 15110, 15111, 15115, 15116, 15120, 15121, 15130, 15131, 15135, 15136, 15150, 15151, 15152, 15155, 15156, 15157, 15200, 15201, 15220, 15221, 15240, 15241, 15260, 15261, 15271, 15272, 15273, 15274, 15275, 15276, 15277, 15278, 15570, 15572, 15574, 15576, 15600, 15610, 15620, 15630, 15650, 15731, 15733, 15734, 15736, 15738, 15740, 15750, 15756, 15757, 15758, 15760, 15770
     
  • Surgery for varicose veins, including perforators and sclerotherapy
​​​36465, 36466, 36470, 36471, 36475, 36476, 36478, 36479, 37500, 37700, 37718, 37722, 37735, 37760, 37761, 37765, 37766, 37780, 37785, 37799
 

Elective (nonemergency) gr​​​ound, air, and sea ambulance transportation, including inpatient hospital-to-hospital transfers


A0140, A0426, A0428, A0430, A0431, A0434, S9960, S9961 


Outpatient private-duty nu​rsing


S9123, S9124 


Day rehabilitation progr​​ams


0931, 0932 


Outpatient radiation ​​therapy


Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore). To access the eviCore website, click here. 


Radiology


Precertification is performed by AIM Specialty Health®. To access the complete list of AIM Specialty Health Diagnostic Imaging Utilization Management Clinical Guidelines, click here.  
  • CT 
  • CTA 
  • Echocardiography services
    • Testing transthoracic echocardiography (TTE) 
    • Stress echocardiography (SE) 
    • Transesophageal echocardiography (TE)
  • MRA 
  • MRI 
  • Nuclear cardiology 
  • ​PET scans 


Prosthetics/orthoses​​​ including: 


  • Custom ankle-foot orthoses

    L1900, L1904, L1907, L1920, L1940, L1945, L1950, L1960, L1970, L1980, L1990, L2106, L2108, L4631​
     
  • Custom knee-ankle-foot orthoses

    L2000, L2005, L2010, L2020, L2030, L2034, L2036, L2037, L2038, L2126, L2128
     
  • Custom knee braces

    L1834, L1840, L1844, L1846, L1860
     
  • ​Custom limb prost​hetics including accessories/components
K1014, L5010, L5020, L5050, L​​5060, L5100, L5105, L5150, L5160, L5200, L5210, L5220, L5230, L5250, L5270, L5280, L5301, L5312, L5321, L5331, L5341, L5510, L5520, L5530, L5535, L5540, L5560, L5570, L5580, L5585, L5590, L5595, L5600, L5610, L5611, L5613, L5614, L5616, L5617, L5618, L5620, L5622, L5624, L5626, L5628, L5629, L5630, L5631, L5632, L5634, L5636, L5637, L5638, L5639, L5640, L5642, L5643, L5644, L5645, L5646, L5647, L5648, L5649, L5650, L5651, L5652, L5653, L5654, L5655, L5656, L5658, L5661, L5665, L5666, L5668, L5670, L5671, L5672, L5673, L5676, L5677, L5678, L5679, L5680, L5681, L5682, L5683, L5684, L5685, L5686, L5688, L5690, L5692, L5694, L5695, L5696, L5697, L5698, L5699, L5700, L5701, L5702, L5703, L5704, L5705, L5706, L5707, L5710, L5711, L5712, L5714, L5716, L5718, L5722, L5724, L5726, L5728, L5780, L5781, L5782, L5785, L5790, L5795, L5810, L5811, L5812, L5814, L5816, L5818, L5822, L5824, L5826, L5828, L5830, L5840, L5845, L5848, L5850, L5855, L5856, L5857, L5858, L5859, L5910, L5920, L5925, L5930, L5940, L5950, L5960, L5962, L5964, L5966, L5968, L5970, L5971, L5972, L5973, L5974, L5975, L5976, L5978, L5979, L5980, L5981, L5982, L5984, L5985, L5986, L5987, L5988, L5990, L5999, L6000, L6010, L6020, L6050, L6055, L6100, L6110, L6120, L6130, L6320, L6350, L6360, L6370, L6400, L6450, L6500, L6550, L6570, L6580, L6582, L6584, L6586, L6588, L6590, L6600, L6605, L6610, L6611, L6615, L6616, L6620, L6621, L6623, L6624, L6625, L6628, L6629, L6630, L6632, L6635, L6637, L6638, L6640, L6641, L6642, L6645, L6646, L6647, L6648, L6650, L6655, L6660, L6665, L6670, L6672, L6675, L6676, L6677, L6680, L6682, L6684, L6686, L6687, L6688, L6689, L6690, L6691, L6692, L6693, L6694, L6695, L6696, L6697, L6698, L6703, L6704, L6706, L6707, L6708, L6709, L6711, L6712, L6713, L6714, L6715, L6721, L6722, L6805, L6810, L6880, L6881, L6882, L6883, L6884, L6885, L6890, L6895, L6900, L6905, L6910, L6915, L6920, L6925, L6930, L6935, L6940, L6945, L6950, L6955, L6960, L6965, L6970, L6975, L7007, L7008, L7009, L7040, L7045, L7170, L7180, L7181, L7185, L7186, L7190, L7191, L7260, L7400, L7401, L7402, L7403, L7404, L7405, L7499
 

Selected durable medi​​​​cal equipment (DME) 


  • Bone growth stimulators

    E0747, E0760
     
  • Bone growth stimulator, electrical, noninvasive, spinal

    Precertification is performed by AIM Specialty Health®. For additional information, refer to the current version of Medical Policy #00.01.66: Musculoskeletal Services.
     
  • Bone-anchored (osseointegrated) hearing aids

    L8690, L8691, L8692, L8693, L8694
     
  • Continuous positive airway pressure (CPAP) devices, bi-level (Bi-PAP) devices, and all supplies

    Precertification is performed by AIM Specialty Health®. To access the complete list of AIM Specialty Health Sleep Disorder Management Diagnostic & Treatment Guidelines, click here.
     
  • Dynamic adjustable and static progressive stretching devices (excludes CPMs)

    E1800, E1802, E1805, E1810, E1812, E1825, E1830
     
  • Electric, power, and motorized wheelchairs including custom accessories

    E1002, E1003, E1004, E1005, E1006, E1007, E1008, E1009, E1010, E1012, E1239, E2291, E2292, E2293, E2294 E2310, E2311, E2312, E2313, E2321, E2322, E2323, E2324, E2325, E2326, E2327, E2328, E2329, E2330, E2331 E2340, E2341, E2342, E2343, E2351, E2373, E2377, E2603, E2604, E2605, E2606, E2607, E2608, E2609, E2613 E2614, E2615, E2616, E2617, E2620, E2621, E2622, E2623, E2624, E2625, E2626, E2627, E2628, E2629, E2630 K0010, K0011, K0012, K0013, K0014, K0056, K0108, K0813, K0814, K0815, K0816, K0820, K0821, K0822, K0823 K0824, K0825, K0826, K0827, K0828, K0829, K0835, K0836, K0837, K0838, K0839, K0840, K0841, K0842, K0843 K0848, K0849, K0850, K0851, K0852, K0853, K0854, K0855, K0856, K0857, K0858, K0859, K0860, K0861, K0862 K0863, K0864, K0890, K0891, K0898
     
  • Insulin pumps

    E0784, E0787, S1034
     
  • Manual wheelchairs with the exception of those that are rented

    E0958, E1002, E1003, E1004, E1005, E1006, E1007, E1008, E1009, E1010, E1012, E1031, E1037, E1038, E1039 E1050, E1060, E1070, E1083, E1084, E1085, E1086, E1087, E1088, E1089, E1090, E1092, E1093, E1100, E1110  E1130, E1140, E1150, E1160, E1161, E1170, E1171, E1172, E1180, E1190, E1195, E1200, E1220, E1221, E1222  E1223, E1224, E1229, E1231, E1232, E1233, E1234, E1235, E1236, E1237, E1238, E1240, E1250, E1260, E1270  E1280, E1285, E1290, E1295, E2291, E2292, E2293, E2294, E2295, E2603, E2604, E2605, E2606, E2607, E2608  E2609, E2613, E2614, E2615, E2616, E2617, E2620, E2621, E2622, E2623, E2624, E2625, E2626, E2627, E2628  E2629, E2630, K0001, K0002, K0003, K0004, K0005, K0006, K0007, K0008, K0009, K0108
     
  • Negative pressure wound therapy

    A6550, A9272, E2402, K0743, K0744, K0745, K0746
     
  • Neuromuscular stimulators

    E0744, E0745, E0764, E0770
     
  • Power operated vehicles (POV)

    E1230, K0800, K0801, K0802, K0812
     
  • Pressure reducing support surfaces including: 
    • Air fluidized bed

      E0194
       
    • Non powered advanced pressure reducing mattress

      E0371, E0373
       
    • Powered air flotation bed (low air loss therapy)

      E0193, E0372
       
    • Powered pressure reducing mattress

      E0277 
  • Push rim activated power assist devices

    E0986
     
  • Repair or replacement of all DME items, as well as orthoses and prosthetics that require precertification

    E2368, E2369, E2370, E2374, E2375, E2376
     
  • Speech gen​erating devices
E2500, E2502, E2504, E2506, E2508, E2510, E2511, E2599, V5336
 

Medica​​​​l foods​


B4149, B4150, B4152, B4153, B4154, B4155, B4157, B4158, B4159, B4160, B4161, B4162, S9433, S9434, S9435 


Hyperbaric oxygen therapy


0413, G0277 


Proton beam ther​​apy


Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore). To access the eviCore website, click here. 


Sleep studies (facility based)


Precertification is performed by AIM Specialty Health®. To access the complete list of AIM Specialty Health Sleep Disorder Management Diagnostic & Treatment Guidelines, click here.
 

All transplant procedures, with the exception of corneal tra​nsplants


0584T, 0585T, 0586T, 15775, 15776, 27415, 27416, 29866, 29867, 32851, 32852, 32853, 32854, 33935, 33945, 38205, 38206, 38207, 38208, 38209, 38210, 38211, 38212, 38213, 38214, 38215, 38230, 38232, 38240, 38241, 38242, 38243, 44133, 44135, 44136, 44137, 47135, 47140, 47141, 47142, 47399, 48160, 48554, 48556, 50320, 50340, 50360, 50365, 50370, 50380, 50547, G0341, G0342, G0343, S2053, S2054, S2060, S2061, S2065, S2103, S2140, S2142, S2150  


Mental health/serious mental illness/substa​​nce abuse


Precertification review for these services is provided by Magellan Healthcare, Inc.
 
  • Mental health and serious mental illness treatment (inpatient/partial hospitalization programs/intensive outpatient programs) 
  • Repetitive transcranial magnetic stimulation (RTMS) 
  • ​Substance abuse treatment (inpatient/partial hospitalization programs/intensive outpatient programs) 


Autism spectrum diso​​​rders 


  • Applied behavioral analysis
    Precertifica​tion review for this service is provided by Magellan Healthcare, Inc. 


Genetic and genomic tests requiring ​​​precertification


Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore). To access the eviCore website, click here. 

The following list is a guide to the types of genetic and genomic tests that require precertification. Due to the volume of tests, it is not possible to list each test separately. To determine if a test requires precertification, please see the complete procedure code list for details. Please note: precertification of genetic and genomic tests applies to commercial members only. 


Hereditary cancer syndrom​es 


  • BRCA gene testing (breast and ovarian cancer syndrome) 
  • Lynch syndrome gene testing 
  • Familial adenomatous polyposis gene testing 
  • PTEN gene testing (Cowden syndrome) 
  • ​General cancer type panels (such as colon, breast, or neuroendocrine cancers) 

Hereditary heart dis​​eases 


  • Long QT syndrome gene testing 
  • ​Aortic dilation or a​neurysm syndrome testing (includes Marfan syndrome) 


Other full gene an​​alysis testing 


  • Cystic fibrosis full gene sequencing and deletion/duplication analysis 
  • ​PMP22 full gene sequencing and deletio​n/duplication analysis (Charcot-Marie-Tooth, hereditary neuropathy) 


Tests for many genetic disorders simultane​​ously 


  • Expanded carrier screening panels (such as Carrier Status DNA Insight®, Counsyl Family Prep Screen, Pan-Ethnic Carrier Screening) 
  • Hearing loss panels 
  • Intellectual disability panels 
  • Noonan spectrum diso​rders panels 


Specialty onc​​​​ology tests


  • Cancer gene expression or protein signature tests (such as OncotypeDX®, MammaPrint®, Afirma®, Prosigna®, HeproDX™) 
  • Tumor molecular profiling (such as FoundationOne®, neoTYPE™, OncoPlexDx®, and many others) 
  • Tissue of origin testing (for cancer of unknown primary) 
  • ​PCA3 testing for prostate cancer 


Pharmacogenomic tes​​ts 


  • Cytochrome P450 metabolism gene testing (CYP2D6, CYP2C9, CYP2C19) 
  • Specialized drug response gene panels (such as Assurex GeneSight®, GeneTrait, Genecept®, Millennium PGTSM
  • Warfarin response testing 
  • ​MGMT methylati​on analysis for glioblastoma 


Other specialty​​​ tests 


  • Coronary artery disease risk testing (such as CorusCAD®, CardioIQ®, APOE, ACE, KIF6) 
  • ​Heart disease risk testing (such as CorusCAD®, CardioIQ®, APOE, ACE, KIF6, MTHFR) 


Geno​​​me-wide tests 


  • Microarray studies 
  • Whole exome testing 
  • Whole genome testing 
  • ​Mitochondrial genome or nuclear testing 


ANY genetic test for more than one gene or c​​​ondition (often includes words like “panel" or “comprehensive" in the name) 


ANY genetic test that will be billed with a ​​non-specific procedure code 


  • Billed with CPT® codes 81400-81408 
  • Billed with an unlisted code: 81479, 81599, 84999 


Specialty drugs requiring pr​​ecertification


All listed brands and their generic equivalents or biosimilars require precertification. This list is subject to change. 


Antineoplastic ag​​ents 


  • Abraxane® - J9264
  • Adcetris® - J9042
  • Alimta® - J9305
  • Amivantamab (pending FDA approval) J9999 and C9399​
  • Avastin® - C9257 and J9035 (Note: Opthalmologic use of Avastin does not require precertification. Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Azedra - A9590
  • Blenrep - J9037
  • Blincyto™ - J9039
  • Cyramza® - J9308
  • Darzalex™ - J9145
  • Darzalex Faspro – J9144
  • Elzonris™ - J9269
  • Enhertu® - J9358
  • Erbitux® - J9055
  • Erwinaze® - J9019
  • Herceptin® - J9355 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Herceptin® Hylecta - J9356
  • Herzuma - Q5113
  • Instiladrin (pending FDA approval) - J3490 and C9399
  • Kadcyla® - J9354
  • Kanjinti™ - Q5117
  • Kyprolis® - J9047
  • Lumoxiti™ - J9313
  • Margenza™ - J9353
  • Mvasi™ - Q5107 (Note: Opthalmologic use of Mvasi does not require precertification.)
  • Ogivri - Q5114
  • Ontruzant - Q5112
  • Padcev- J9177
  • Pemfexy - J9304
  • Pepaxto® - J3590 and C9080​
  • Perjeta® - J9306
  • Phesgo – J9316
  • Polivy - J9309
  • Poteligeo® - J9204
  • Provenge® - Q2043
  • Riabni™ - Q5123
  • Rituxan® - J9312 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Rituxan Hycela™ - J9311
  • Ruxience™ - Q5119
  • Sarclisa® - J9227
  • Taclantis™ (pending FDA approval) - J3490 and C9399
  • Tecartus™ (pending FDA approval) Q2053
  • Trazimera™ - Q5116
  • Trodelvy™ - J9317
  • Truxima™ - Q5115
  • Xofigo®* - A9606
  • Yervoy™ - J9228
  • Zepzelca – J9223
  • Zevalin®* - A9543
  • Zirabev™ - Q5118 (Note: Ophthalmologic use of Zirabev does not require precertification.)​
  • Zynlonta™ J3590 and C9399​
     
    * Prec​ertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore). To access the eviCore website, click here. 


Anti PD-1/PD-L1 human monoclonal antibodies


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year. 
  • Bavencio® - J9023
  • Imfinzi™ - J9173
  • Jemperli™ - J3590 and C9399​
  • Keytruda™ - J9271
  • Libtayo® - J9119
  • Opdivo® - J9299
  • Retifanlimab (pending FDA approval) - J9999 and C9399​
  • ​​Tecentriq™ - J9022 


Bone-modifying a​​gents 


  • Evenity™ - J3111
  • Prolia® - J0897
  • ​Xgeva® - J0897 


Botulinum toxin agent​​s 


  • ​Botox® - J0585 


Chemotherapy-induced n​​​ausea and vomiting (CINV) agents


  • ​Sustol® - J1627 


Chimeric antigen receptor (CAR-T) thera​​pies


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.  

  • Abecma® - J3490, J3590, and C9399
  • ​Breyanzi® - C9067 and J3590​
  • ​​Ciltacabtagene Autoleucel (pending FDA approval) – J3490, J3590, and C9399​
  • Kymriah™ - Q2042
  • Tecartus™ - Q2053​
  • ​Yescarta™ - Q2041 
  • ​​Chimeric antigen receptor t-cell (car-t) therapy; car-t cell administration, autologous – 0540T​​



Colony stimulating​​ factors 


  • Fulphila™ - Q5108
  • Lapelga (pending FDA approval) - J3490, J3590, and C9399
  • Neulasta® - J2505 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Neulasta Onpro™ - J2505
  • Neupogen® - J1442
  • Nivestym™ - Q5110
  • Nyvepria™ – Q5122
  • Rolontis® (pending FDA approval) - J3490 and C9399
  • Udenyca™ - Q5111
  • ​Ziextenzo® - Q5120


Endocrine/m​​etabolic agents 


  • Acthar H.P.® - J0800
  • Cosyntropin depot (pending FDA approval) - J3490, J3590, and C9399
  • Lutathera®* - A9513 and A9699
  • Makena® - J1726 and J1729
  • Sandostatin® LAR - J2353
  • Somatuline® depot - J1930 
Precertification review is provided by CareCore National, LLC d/b/a eviCore healthcare (eviCore). To access the eviCore website, click​ ​here. ​​


Enzyme replacement agen​​​ts


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.  
  • Aldurazyme® - J1931
  • Avalglucosidase Alfa (pending FDA approval) - C9399 and J3590​
  • Brineura™ - J0567
  • Cerezyme® - J1786
  • Elaprase® - J1743
  • Elelyso® - J3060
  • Fabrazyme® - J0180
  • Kanuma® - J2840
  • Lumizyme® - J0221
  • Mepsevii™ - J3397
  • Naglazyme® - J1458
  • Pegunigalsidase Alfa (pending FDA approval) J3590
  • Replagal® (pending FDA approval) - J3490  
  • Revcovi™ - J3590 and C9399
  • Vimizim™ - J1322
  • ​VPRIV® - J3385 


Gen​e therapy


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Luxturna™ - J3398
  • Roctavian (pending FDA approval) - J3490 and C9399​
  • Zolgensma® - J3399
  • ​Zynte​glo (pending FDA approval) - J3490, J3590, and C9399 


Hemophilia/Coagulation fac​​tors


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.  
  • Advate® - J7192
  • Adynovate® - J7207
  • Afstyla® - J7210
  • Alphanate® - J7186
  • Alphanine SD® - J7193
  • Alprolix® - J7201
  • Bebulin VH® - J7194
  • Bebulin® - J7194
  • Benefix® - J7195
  • Coagadex® - J7175
  • Corifact® - J7180
  • Eloctate® - J7205
  • Esperoct® - J7204
  • Feiba NF® - J7198
  • Feiba VH® - J7198
  • Fibryga® - J7177
  • Helixate FS® - J7192
  • Hemlibra® - J7170
  • Hemofil-M® - J7190
  • Humate-P® - J7187
  • Hyate-C® - J7191
  • Idelvion® - J7202
  • Ixinity® - J7199
  • Jivi® - J7199 and J7208
  • Koate-DV I® - J7190
  • Kogenate FS® - J7192
  • Kovaltry® - J7207 and J7211
  • Monoclate-P® - J7190
  • Mononine® - J7193
  • Novoeight® - J7182
  • Novoseven RT® - J7189
  • Novoseven® - J7189
  • Nuwiq® - J7209
  • Obizur® - J7188
  • Profilnine SD® - J7194
  • Rebinyn® - J7203
  • Recombinate®​ - J7192
  • RiaSTAP® - J7178
  • Rixubis® - J7195 and J7200
  • Sevenfact® – J7212
  • Tretten® - J7181
  • Vonvendi® - J7179 and J7199
  • Wilate® - J7183
  • ​Xyntha® - J7185 


Hyaluronate acid​​​ products 


  • Cingal (pending FDA approval) - J3490
  • Durolane® - J7318
  • Euflexxa™ - J7323
  • Gel-One® - J7326
  • Gelsyn-3™ - J7328
  • GenVisc 850® - J7320
  • Hyalgan® - J7321
  • Hymovis® - J7322
  • Supartz® - J7321
  • Synojoynt - J7331
  • Triluron - J7332
  • TriVisc™ - J7329
  • ​VISCO-3® - J7321


Immunologica​​l agents 


  • Actemra® - J3262
  • Anifrolumab (pending FDA approval) - C9399 and J3590​
  • Avsola™ - Q5121
  • Benlysta® - J0490
  • Entyvio™ - J3380
  • Ilumya™ - J3245
  • Inflectra™ - Q5103
  • Ixifi™ - Q5109
  • Orencia® - J0129
  • Remicade® - J1745 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Renflexis™ - Q5104
  • Simponi® Aria - J1602
  • Stelara® - J3357 and J3358  


Intravenous Immune Globulin/Su​​bcutaneous Immune Globulin (IVIG/SCIG)


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
 
  • Intravenous Immune Globulin (IVIG) 
    • Asceniv® - J1554
    • Bivigam® - J1556
    • Carimune® - J1566
    • Flebogamma® - J1572
    • Flebogamma-Dif® - J1572
    • Gammagard Liquid® - J1569
    • Gammagard S/D® - J1566
    • Gammaked® - J1561
    • Gammaplex® - J1557
    • Gamunex-C® - J1561
    • Octagam® - J1568
    • Panzyga® - J1599
    • Privigen® - J1459 
  • Subcutaneous Immune Globulin (SCIG)
    • Cutaquig® - J7799
    • Cuvitru® - J1555
    • Hizentra® - J1559
    • Hyqvia® - J1575
    • ​​Xe​​​mbify® - J1558 


Multiple​ scleros​is ​agents


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.
  • Lemtrada® - J0202
  • Ocrevus™ - J2350
  • ​Ty​sabri® - J2323 


Ophthalmi​​​c agents 


  • Abicipar (pending FDA approval) - J3490, J3590, and C9399
  • Beovu® - J0179
  • Eylea® - J0178
  • Lucentis® - J2778 (Precertification requirements apply to all FDA-approved biosimilars to this reference product.)​
  • ​Tepezza® - J3241


Pulmonary arterial hyperten​​​sion


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year. 
  • Flolan® - J1325
  • Remodulin® - J3285
  • Revatio® - J3490 and C9399
  • Trevyent (pending FDA approval) - J3490 and C9399
  • Tyvaso® - J7686
  • Veletri® - J1325
  • Ventavis® - Q4074 


Respiratory ag​​​ents 


  • Cinqair® - J2786
  • Synagis® - 90378
  • ​Xolair® - J2357 


Respiratory enzyme​​s (Alpha-1 antitrypsin)


All drugs that can be classified under this header require precertification. This includes any unlisted brand or generic names, or biosimilars, as well as new drugs that are approved by the FDA in that class during the course of the benefit year.  
  • Aralast - J0256
  • Glassia™ - J0257
  • Prolastin® - J0256
  • ​Zemaira® - J0256 


Miscellaneous therapeuti​​​c agents 


  • Adakveo® - J0791
  • Ampligen® (pending FDA approval) - J3490
  • Cosela® - C9078 and J3590​
  • Crysvita - J0584
  • Efgartigimod (pending FDA approval) - C9399 and J3590
  • Evkeeza™ - C9079 and J3590​
  • Evianacumab (pending FDA approval) J3490, J3590, and C9399
  • Exenatide sustained-release ITCA 650 (pending FDA approval) - J3490
  • Gamifant® - J9210
  • Givlaari - J0223
  • Ilaris - J0638
  • Inclisiran (pending FDA approval) J3490, J3590, and C9399
  • Krystexxa - J2507
  • Narsoplimab (pending FDA approval) - C9399 and J3590​
  • Onpattro® - J0222
  • Oxlumo™ – J0224
  • Radicava - J1301
  • Reblozyl® - J0896
  • Remune (pending FDA approval) - J3490
  • Rethymic™ (RVT-802) (pending FDA approval) - J3490, J3590, and C9399
  • Soliris® - J1300 (Precertification requirements apply to all FDA-approved biosimilars to this originator product.)
  • Spinraza - J2326
  • Sutimlimab (pending FDA approval) - C9399 and J3590
  • Teplizumab (pending FDA approval) - C9399 and J3590
  • Trogarzo - J1746
  • Ultomiris™ - J1303
  • Uplizna – J1823
  • Vyepti™ - J3032
  • Xiaflex® – J0775 


Revisio​​​ns


​ 

​​

July 1, 2021


The following revisions were incorporated into the July 1, 2021 update.​

Additions, codes added

Antineoplastic agents

  • Amivantamab (pending FDA approval) – J9999 and C9399
  • Margenza™ - J9353
  • Pepaxto® - C9080 and J3590
  • Riabni™ - Q5123

Anti-PD-1/PD-L1-human monoclonal antibodies

  • Jemperli™ - J3590 and C9399
  • Retifanlimab (pending FDA approval) – J9999 and C9399

Chimeric antigen receptor (CAR-T) agents

  • Abcema® - J3490, J3590, and C9399
  • Breyanzi® – C9067 and J3590

Endocrine/metabolic agents

  • Cosyntropin depot (pending FDA approval) – J3490, J3590, and C9399

Enzyme replacement agents

  • Avalglucosidase Alfa (pending FDA approval) – C9399 and J3590

Gene replacement agent

  • Roctavian (pending FDA approval) - J3490 and C9399

Immunological agents

  • Anifrolumab (pending FDA approval) – C9399 and J3590

Miscellaneous therapeutic agents

  • Cosela® - C9078 and J3590
  • Efgartigimod (pending FDA approval) – C9399 and J3590
  • Evkeeza™ – C9079 and J3590
  • Narsoplimab (pending FDA approval) – C9399 and J3590
  • Oxlumo™ – J0224
  • Sutimlimab (pending FDA approval) – C9399 and J3590
  • Teplizumab (pending FDA approval) – C9399 and J3590

Deletions, codes added 

Antineoplastic agents

  • Azedra Dosimetric – A9590
  • Margenza™ - J3490, J3590, and C9399
  • Riabni™ - J3490, J3590, and C9399

Anti-PD-1/PD-L1-human monoclonal antibodies

  • Dostarlimab (pending FDA approval) – J3490, J3590, C9399

Chimeric antigen receptor (CAR-T) therapies

  • Ideacabtagene Vicleucel (pending FDA approval) - J3490, J3590, and C9399
  • Lisocabtagene maraleucal (pending FDA approval) – J3490, J3590, and C9399

Duchenne muscular dystrophy agents​

  • Casemirsen (pending FDA approval) – J3490, J3590, and C9399
  • Vitolarsen (pending FDA approval) - J3490, J3590, and C9399

Gene replacement agent

  • Valrox (pending FDA approval) - J3490 and C9399

Hemophilia/Coagulation factors

  • Autoplex T – J7198
  • Bioclate – J7192
  • Fibryna – J7178
  • Hyate C – J7191
  • Monarc – J7190
  • Proplex T – J7194
  • Refacto – J7192

Intravenous Immune Globulin/Subcutaneous Immune Globulin (IVIG/SCIG

  • Intravenous Immune Globulin (IVIG)
  • Gammagard® - J1569

Ophthalmic agents

  • Macugen® - J2503
  • Ranibizumab Biosimilar (pending FDA approval) – J3490, J3590, and C9399

Miscellaneous therapeutic agents

  • Inebilizumab (pending FDA approval) – J3490 and C9399


Modifications


For Antineoplastics agents, drug name Lonca changed to Zynlonta™.  Codes of J3590 and C9399 remain the same.

Tecartus™ moved from Antineoplastics agents to Chimeric antigen receptor (CAR-T) therapies.  Code Q2053 remains the same.

Chimeric antigen receptor t-cell (car-t) therapy; car-t cell administration, autologous moved from Antineoplastics agents to Chimeric antigen receptor (CAR-T) therapies.  Code 0540T remains the same.

Heading Gene therapy changed to Gene replacement therapy.

For Gene replacement therapy, drug name Valrox changed to Roctavian.  Codes of J3490 and C9399 remain the same.​​

CPT Copyright 2021 American Medical Association. All rights reserved. CPT® is a registered trademark of the American Medical Association.  

AmeriHealth HMO, Inc.